HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Ascentage Pharma (6855.HK) Placement - Thoughts on The Placing Price and the Outlook

Pre-IPO Shanghai Jin Jiang International Hotels - The Pain Points and the Outlook

What Happens to China Healthcare? - The Soaring Shares, the Turning Point, and the Top Picks

Pre-IPO LXJ International Holdings - The Pain Points and the Outlook

Pre-IPO Mabwell (Shanghai) Bioscience - The ADC Technology Is Outdated

Pre-IPO Bama Tea - The Business Model, the Challenges and the Outlook

Equity Capital Markets

<ul>
<li>BUSY MING operates under the franchise model, under which franchisees and BUSY MING form collaboration and a virtuous cycle, benefiting from the ecological logic of high turnover.</li>
<li>However, the potential risk is increasing homogeneous competition. Price wars and competitors' rapid expansion would further squeeze the profit margin of BUSY MING and lead to market oversaturation.</li>
<li>The current high growth may not sustain.BUSY MING clearly hopes to successfully IPO during the current peak period of performance, but investors may face a decline in performance after IPO.</li>
</ul>


BUSY MING operates under the franchise model, under which franchisees and BUSY MING form collaboration and a virtuous cycle, benefiting from the ecological logic of high turnover.
However, the potential risk is increasing homogeneous competition. Price wars and competitors' rapid expansion would further squeeze the profit margin of BUSY MING and lead to market oversaturation.
The current high growth may not sustain.BUSY MING clearly hopes to successfully IPO during the current peak period of performance, but investors may face a decline in performance after IPO.


Pre-IPO Busy Ming Group - Concerns Behind the High Growth